SEC Form 4 · accession 0000899243-17-008828
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Olivier Danos
Officer — Chief Scientific Officer
Period of report
Mar 27, 2017
Accepted (ET)
Mar 29, 2017 · 5:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $20.35 | Mar 27, 2017 | A | 100,000 | A | — | Mar 26, 2027 | Common Stock | 100,000 | 100,000 | D |
Explanation of responses
- F125% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 3/27/2018 while the optionee provides continuous service to the Issuer.